Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
THTX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-0.40
vs -0.96
Q3.23
N/A
-0.03
vs -0.32
Q4.23
N/A
-0.08
vs -0.36
Q1.24
N/A
-0.10
vs -0.44
Q2.24
+105%
0.02
vs -0.40
Q3.24
+300%
0.06
vs -0.03
Q4.24
N/A
-0.09
vs -0.08
Q1.25
+102%
0
vs -0.10
Q2.25
N/A
-0.01
vs 0.02
Q3.25
-25%
0.04
vs 0.06
Sales Growth
YoY
Current
Estimates
Q2.23
-9%
17.5M vs 19.3M
Q3.23
+0%
20.9M vs 20.8M
Q4.23
+9%
23.5M vs 21.4M
Q1.24
-19%
16.1M vs 19.9M
Q2.24
+25%
22M vs 17.5M
Q3.24
+8%
22.6M vs 20.9M
Q4.24
+7%
25M vs 23.5M
Q1.25
+18%
19M vs 16.1M
Q2.25
-21%
17.5M vs 22M
Q3.25
-4%
21.6M vs 22.6M
Return on Equity
QoQ
Q2.23
+24%
0.24
vs 0.32
Q3.23
+2%
0.02
vs 0.24
Q4.23
+13%
0.13
vs 0.02
Q1.24
+18%
0.18
vs 0.13
Q2.24
-4%
-0.04
vs 0.18
Q3.24
-16%
-0.16
vs -0.04
Q4.24
+31%
0.31
vs -0.16
Q1.25
0%
-0.00
vs 0.31
Institutionnal Ownership
QoQ
Q2.23
42
42
vs 42
NA
Q3.23
30
30
vs 42
-29%
Q4.23
32
32
vs 30
7%
Q1.24
35
35
vs 32
9%
Q2.24
34
34
vs 35
-3%
Q3.24
39
39
vs 34
15%
Q4.24
42
42
vs 39
8%
Q1.25
38
38
vs 42
-10%
businesswire.com
8 hours ago
globenewswire.com
14 hours ago
globenewswire.com
18 hours ago
Relative Strength
THTX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.03 ( 1.20%)
Relative Strenght
94
Volume Buzz
-94%
Earning Acce
No
Dist 52w H.
19%Forecast
400%2026-Revenue
11983%2026-EPS
-846%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
Cantor Fitzgerald
initialisePrevious: Not converted
2022-11-17
Now: Overweight